论文部分内容阅读
目的分析2型糖尿病肾病患者行丹红联合前列地尔疗法的临床效果。方法选取2013年1月-2015年6月医院接收的2型糖尿病肾病患者85例,依照所采用的疗法不同而分为研究组40例与对照组45例,对照组患者行基础疗法(降压、抗凝等),研究组患者于上述基础上行丹红、前列地尔联合疗法,评定预后效果。结果调查结果显示,2组2型糖尿病肾病患者预后24h蛋白尿含量、白蛋白排泄存比较差异有统计学意义(P<0.05)。2组患者临床预后不良反应比较差异无统计学意义(P>0.05)。结论临床针对2型糖尿病肾病患者行丹红、前列地尔联合疗法作用突出,可改善蛋白尿含量,不良反应轻微,值得推广应用。
Objective To analyze the clinical effect of Danhong combined with alprostadil therapy in patients with type 2 diabetic nephropathy. Methods From January 2013 to June 2015, 85 patients with type 2 diabetic nephropathy received by the hospital were divided into study group (40 cases) and control group (n = 45) according to different treatments. Patients in the control group underwent basic therapy , Anticoagulation, etc.), the study group patients on the basis of Danhong, alprostadil combination therapy to assess the prognosis. Results The results of the survey showed that the proteinuria and albumin excretion of 24 patients with type 2 diabetic nephropathy had statistically significant differences (P <0.05). Two groups of patients with clinical prognosis adverse reactions were no significant difference (P> 0.05). Conclusions Clinic patients with type 2 diabetic nephropathy are treated with Danhong and the combination therapy of alprostadil is superior, which can improve the proteinuria content with slight adverse reactions and is worth popularizing and applying.